Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-11-21

Clinical Trial Update: Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating dupilumab for moderate to severe chronic hepatic pruritus have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dupilumab (dupilumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Pruritus | Phase 2 | Status: COMPLETED | Results posted: 2025-11-21